PC
PTCT icon

Polar Capital’s PTC Therapeutics PTCT Stock Holding History

Polar Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$2.34M Buy
+50,000
New +$2.46M 0.02% 238

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polar Capital's PTCT Position: Q3 2020 in Review

Polar Capital opened a new position in PTC Therapeutics (PTCT) in Q3 2020: 50,000 shares worth $2.34M. The stake represents 0.02% of the portfolio and ranks #238 among its holdings.

196 funds tracked by Wall St. Rank hold PTCT as of Q3 2020.

  • Polar Capital held 50,000 shares of PTC Therapeutics worth $2.34M as of Q3 2020.
  • PTC Therapeutics was a new Polar Capital position in Q3 2020.
  • PTC Therapeutics made up 0.02% of Polar Capital's portfolio in Q3 2020, its #238 holding.
  • 196 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.